The use of immune checkpoint inhibitors, a form of immunotherapy, has represented a significant breakthrough in cancer treatment and markedly improved outcomes for patients with cancer. However, the introduction of these novel drugs has also brought new adverse events that differ from those associated with traditional chemotherapy. To support the well-being and enhanced life expectancy of patients, it is crucial that healthcare professionals are well informed about immune-related adverse events (irAEs) and vigilant in recognising their early signs. Conducting baseline tests before initiating immunotherapy treatments can provide valuable information for the early identification of these adverse events. By proactively addressing irAEs, healthcare professionals can optimise patient experiences during cancer treatment and improve overall treatment outcomes.